Home Dementias Revolutionary CRISPR-based genome editing doubles life expectancy in mice with Glioblastoma, improving...
Dementias

Revolutionary CRISPR-based genome editing doubles life expectancy in mice with Glioblastoma, improving overall survival rate by about 30% : braincancer

By wordpressadmin
0
122

This is fantastic news and grounds for a real breakthrough but a couple caveats: the journey from mice to humans is a long one. Further, some of the biggest challenges remain in targeted delivery of therapy. However, it warms my heart to see such progress happening in my lifetime.

Continue Reading to the Source

Previous article“Successfully” completed my radiation treatment this week!
Next articleYouths Day Out – Brain Tumour Society (Singapore) Ltd.
wordpressadmin

RELATED ARTICLES

Dementias

He got his last chemo on Saturday. The same day MRI showed that cancer is back. 8-10 new spots. In only 3 months since...

wordpressadmin - 0
submitted by /u/szejdy Continue Reading to the Source
Read more
Dementias

ITS NOT A TUMOR

wordpressadmin - 0
submitted by /u/WeirdlyTechnical Continue Reading to the Source
Read more
Dementias

Living Through Covid-19 as a Cancer Patient or Survivor

wordpressadmin - 0
https://www.cancertalkfoundation.org/post/living-through-covid-19-as-a-cancer-patient-or-survivor submitted by /u/CancerTalkFoundation Continue Reading to the Source
Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

Alzheimer’s Disease wordpressadmin - 0
The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...
Read more

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

Alzheimer’s Disease wordpressadmin - 0
In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...
Read more

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

Alzheimer’s Disease wordpressadmin - 0
A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...
Read more

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

Alzheimer’s Disease wordpressadmin - 0
An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in...
Read more
Load more

Recent Comments

A WordPress Commenter on Hello world!